Surprising magic of CD24 beyond cancer

被引：1

作者：

Wang, He ^{[1
]}

Shi, Peng ^{[2
]}

Shi, Xinyu ^{[3
]}

Lv, Yaqing ^{[4
]}

Xie, Hongwei ^{[1
]}

Zhao, Hai ^{[1
]}

机构：

[1] Qingdao Univ, Dept Neurosurg, Affiliated Hosp, Qingdao, Peoples R China

[2] Qingdao Univ, Affiliated Hosp, Dept Emergency Surg, Qingdao, Peoples R China

[3] Qingdao Univ, Dept Radiol, Affiliated Hosp, Qingdao, Peoples R China

[4] Qingdao Univ, Affiliated Hosp, Dept Outpatient, Qingdao, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 14卷

关键词：

CD24; CD47; innate checkpoint; non-neoplastic; autoimmune diseases; Covid-19; neurological disease; metabolic diseases; HEAT-STABLE ANTIGEN; INDEPENDENT PROGNOSTIC MARKER; CENTRAL-NERVOUS-SYSTEM; AUTOREACTIVE T-CELLS; LINEAGE DIFFERENTIATION; MONOCLONAL-ANTIBODIES; GENE POLYMORPHISMS; PANCREATIC-CANCER; SURFACE-ANTIGEN; BONE-MARROW;

D O I：

10.3389/fimmu.2023.1334922

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

CD24 has emerged as a molecule of significant interest beyond the oncological arena. Recent studies have unveiled its surprising and diverse roles in various biological processes and diseases. This review encapsulates the expanding spectrum of CD24 functions, delving into its involvement in immune regulation, cancer immune microenvironment, and its potential as a therapeutic target in autoimmune diseases and beyond. The 'magic' of CD24, once solely attributed to cancer, now inspires a new paradigm in understanding its multifunctionality in human health and disease, offering exciting prospects for medical advancements.

引用

页数：12

共 50 条

[31] Clinical significance of CD24 as a predictor of bladder cancer recurrence
Liu, Chunxiao
Zheng, Shaobo
Shen, Haiyan
Xu, Kai
Chen, Jie
Li, Hulin
Xu, Yawen
Xu, Abai
Chen, Binshen
Kaku, Haruki
Nasu, Yasutomo
Kumon, Hiromi
Huang, Peng
Watanabe, Masami
ONCOLOGY LETTERS, 2013, 6 (01) : 96 - 100
[32] CD24 is a biomarker for prognosis and therapeutic target in bladder cancer
Smith, SC
Nitz, MD
Frierson, HF
Theodorescu, D
MODERN PATHOLOGY, 2006, 19 : 162A - 162A
[33] CD24 polymorphisms in breast cancer: impact on prognosis and risk
Buck, Katharina
Hug, Sarah
Seibold, Petra
Ferschke, Irmgard
Altevogt, Peter
Sohn, Christof
Schneeweiss, Andreas
Burwinkel, Barbara
Jaeger, Dirk
Flesch-Janys, Dieter
Chang-Claude, Jenny
Marme, Frederik
BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (03) : 927 - 937
[34] Blockade of CD24 sensitizes pancreatic cancer to Kras inhibitors
Wei, Yongkun
Liu, Minghui
Yen, Er-Yen
Yao, Jun
Nguyen, Phuoc T.
Wang, Xiaofei
Yang, Zecheng
Yousef, Abdelrahman
Pan, Dean
Jin, Yanqing
Theady, Madelaine S.
Park, Jangho
Cai, Yiming
Takeda, Mitsunobu
Vasquez, Matthew
Zhou, Yong
Zhao, Hong
Viale, Andrea
Wang, Huamin
Zhao, Dan
DePinho, Ronald A.
Yao, Wantong
Ying, Haoqiang
CANCER RESEARCH, 2024, 84 (06)
[35] CD24 expression predicts disease progression in prostate cancer
Nature Clinical Practice Urology, 2005, 2 (4): : 154 - 154
[36] CD24 regulates cancer stem cell like traits in bladder cancer
Oki, Akira
Hoque, Mohammad Obaidul
CANCER RESEARCH, 2019, 79 (13)
[37] CD24 IN TUMORS Inhibiting phagocytosis
Dempsey, Laurie A.
NATURE IMMUNOLOGY, 2019, 20 (09) : 1089 - 1089
[38] CTEN is Downstream Target of CD24
Saira, S. S.
Otifi, H. O. Hassan
Ghamdi, S. G. Saleh
Akhlaq, M. A. Maham
Ilyas, M. I.
JOURNAL OF PATHOLOGY, 2016, 240 : 33 - 33
[39] CD24 Polymorphism and Multiple Sclerosis
Javier Gonzalez, Sergio
Ignacio Rojas, Juan
Ana Redal, Maria
Patrucco, Liliana
Correale, Jorge
Cristiano, Edgardo
Francisco Argibay, Pablo
NEUROLOGY, 2009, 72 (11) : A376 - A376
[40] CD47 predominates over CD24 as a macrophage immune checkpoint in cancer
Meglan, Anna
Allen, Juliet
Vaccaro, Kyle
Velarde, Jose
Chen, Victor
Ribeiro, Juliano
Blandin, Jasmine
Mishra, Ranjan
Ho, Raymond
Love, Jennifer
Reinhardt, Ferenc
Bell, George W.
Chen, Jin
Weinberg, Robert
Yang, Dian
Weissman, Jonathan
Weiskopf, Kipp
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)

← 1 2 3 4 5 →